Articles

The current treatment landscape for patients with HER2-low metastatic breast cancer

BJMO - volume 18, issue 4, june

K. Punie MD, G. Jerusalem MD, PhD, I. Deleu MD, A. Gombos MD, T. Feys MBA, MSc, F.P. Duhoux MD, PhD

SUMMARY

HER2 overexpression has been a therapeutic target in breast cancer (BC) for many years and the development of anti-HER2 therapies has markedly improved the outcome of patients exhibiting high levels of HER2 expression. In this, the HER2 status of patients was traditionally defined in a binary fashion, in which patients with high levels of HER2 expression were classified as HER2-positive, while all the rest were denominated as HER2-negative. Despite being classified as HER2-negative; the majority of these BCs do express some level of HER2. Until recently, however, these low levels of HER2 expression did not have any therapeutic implications. This has changed with the publication of the DESTINY-Breast04 (DB-04) study in which trastuzumab deruxtecan (T-DXd) was shown to significantly improve the progression-free (PFS) and overall survival (OS) of patients with HER2-low metastatic BC. These findings require a recalibration of the treatment paradigm for patients with advanced BC. Furthermore, the increased interest in HER2-low BC led to questions on the biology, epidemiology, heterogeneity, and prognostic relevance of HER2-low disease and confronts physicians with the challenge of incorporating the treatment of HER2-low disease in the rapidly evolving treatment landscape for patients with hormone-receptor-positive (HR+) and triple-negative BC (TNBC).

(BELG J MED ONCOL 2024;18(4):141–51)

Read more

New oncology reimbursements in Belgium

BJMO - volume 18, issue 4, june

T. Feys MBA, MSc

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J MED ONCOL 2024;18(4):176)

Read more

Highlights from ASCO GU 2024

BJMO - volume 18, issue 3, may

A. Enguita PhD, T. Feys MBA, MSc

SUMMARY

From January 25th until the 27th of January, San Francisco once again formed the background for the yearly high mass in urological cancer. During the 2024 ASCO Genitourinary cancers symposium, the latest clinical and scientific advances in the management of urothelial, prostate, and renal cell cancer were presented. This report will provide a brief overview of the key presentation at this years’ meeting.

(Belg J Med Oncol 2024;18(3):109–14)

Read more

New oncology reimbursements in Belgium

BJMO - volume 18, issue 3, may

T. Feys MBA, MSc

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J MED ONCOL 2024;18(3):119)

Read more

Updates in the management of renal cell Carcinoma

BJMO - 2024, issue Special, march 2024

A. Enguita PhD, T. Feys MBA, MSc

The opening session of the 2024 Belgian Multidisciplinary Meeting on Urological Cancers (BMUC) highlighted key advancements in renal cell carcinoma (RCC) management. Prof. Christine Gennigens (ULiège, Liège, Belgium) presented current and future strategies for first-line metastatic RCC treatment, emphasising options such as immunotherapy (IO) dual combinations, IO plus tyrosine kinase inhibitor (TKI) regimens, TKI monotherapy, and triplet therapies. Additionally, Prof. Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discussed the promising outcomes of stereotactic ablative body radiotherapy (SABR) in primary RCC, underscoring its advantages over traditional approaches like surgery or thermal ablation.

Read more

How to implement PSMA radioligand therapy in Belgium

BJMO - 2024, issue Special, march 2024

J. Collins PhD, T. Feys MBA, MSc

During the 11th Belgian Multidisciplinary Meeting on Urological Cancers (BMUC) 2024, Prof. Dr. Karolien Goffin (University Hospitals Leuven), Dr. Carlos Artigas (Institut Jules Bordet, Brussels) and Prof. Dr. Nadia Withofs (CHU de Liège) discussed the current challenges in implementing prostate-specific membrane antigen (PSMA) radioligand therapy in Belgium.

Read more

Late-breaking session on uro-oncology

BJMO - 2024, issue Special, march 2024

J. Blokken PhD, PharmD, T. Feys MBA, MSc

The second day of BMUC 2024 kicked off with the late-breaking session on uro-oncology. During this session, three recent clinical trials with important implications for daily clinical practice were discussed and critically interpreted. First, Prof. Piet Ost (University Hospital Ghent) walked us through the results of the GETUG-AFU18 trial. Thereafter, Dr. Marco Gizzi (Institut Roi Albert II Cliniques universitaires Saint-Luc) shared his insights on the potential caveats of the KEYNOTE-564 trial after which Dr. Alexander Giesen (University Hospitals Leuven) closed the session with a presentation on the PREVENT trial.

Read more